Colon Cancer Linked to Mouth Bacteria

Colon Cancer Linked to Mouth Bacteria  Scientific American

Colon Cancer Linked to Mouth Bacteria

Colon Cancer Linked to Mouth Bacteria

Sustainable Development Goals and Genomic Research on Fusobacterium Nucleatum in Colon Cancer

April 15, 2024

By Maggie Chen

Computer illustration of orange worm like bacteria on green background.

Fusobacterium bacteria. (Image credit: Kateryna Kon/Science Photo Library/Getty Images)

A healthy colon is a marvelously effective organ that squeezes nutrients and water out of food while pumping out waste. But sometimes small clumps of abnormal cells grow on the colon’s lining and turn into cancer. Colon cancer is relatively common but tricky to catch; it can only be confirmed with a colonoscopy or surgery. And a recent, so-far-unexplained rise in colon cancer rates among younger people has ramped up urgency in learning more about how the disease works—and how to prevent it.

Genomic Research on Fusobacterium Nucleatum and its Link to Colon Cancer

Pinning down colon cancer’s genetic or environmental causes has been a complex and long-running quest, but a new study in Nature points to a promising clue: a bacterium typically found in the human mouth. The study found that a specific subtype, or clade, within a subspecies of Fusobacterium nucleatum was linked to colon cancer growth and progression. These results, the study authors say, could lead to better noninvasive diagnostic methods for colon cancer and could even suggest new therapies targeting these bacteria for tumor elimination.

Fusobacterium Nucleatum and its Association with Colon Cancer

F. nucleatum, associated with dental plaque and gingivitis, occurs naturally in the mouth microbiome. A decade ago scientists discovered that the bacterium was also found in colon cancer more often than in normal colon tissue. “This was particularly interesting because this microbe in noncancerous individuals is usually not present below the [mouth],” says the new study’s co-senior author Susan Bullman, a biologist at the Fred Hutchinson Cancer Center.

Research Methodology and Findings

To further explore the microbe’s relationship to colon cancer, Bullman and her colleagues conducted extensive sequencing on F. nucleatum within colon cancer tumors and looked at how the microbe influenced the intestinal environment. The team first analyzed the genomes of F. nucleatum found in colon tumors in order to compare them with those found in the mouth. It collected colon tumors from approximately 100 people and then broke up the tumors and placed them on agar plates to allow the microbes present to grow.

After isolating the F. nucleatum from these cultures, the scientists performed a process called long-read sequencing to get a comprehensive look at the bacterium’s genome. Most traditional sequencing methods rely on what scientists call “short reads”—which is like “assembling a puzzle where you’re not able to get the whole picture,” says the study’s first author, Martha Zepeda-Rivera. “With long-read sequencing, it’s like taking a picture with your camera, where you get the entire picture.”

The team compared these sequences from the colon cancer tissues with those of F. nucleatum from the mouth of healthy individuals. This revealed two main clades within a subspecies (called F. nucleatum animalis) that were distinguished by differences in DNA bases and patterns of encoded proteins. Bacteria in the two clades also had distinct appearances under the microscope: specimens in the second clade were longer and thinner than those from the first.

F. nucleatum animalis from the colon tumors fell overwhelmingly into the second clade. This clade’s genomes seemed to code for characteristics that would help the bacteria survive the perilous journey from the mouth to the intestine—such as the ability to gain nutrients in hostile environments (such as an inflamed gastrointestinal tract) or to better invade cells. These microbes also have “one of the most potent acid-resistant systems” found in bacteria, which lets them tolerate the stomach’s acidic environment, explains Christopher Johnston, a geneticist at Fred Hutchinson Cancer Center and co-senior author of the study.

Implications and Future Research

The findings suggested that the microbes in the second clade were more strongly associated with colon cancer, leading the researchers to explore further how these microbes interacted with the intestine in a mouse model. They gave one group of mice a single oral dose of F. nucleatum animalis from clade 1 and another a dose of clade 2 and then counted the number of tumors that formed. Mice in the clade 2 group developed a significantly higher number of large intestinal tumors in comparison with those given clade 1 bacteria or a nonbacterial control.

When the scientists measured metabolic molecules inside tumors from the mice with clade 2 bacteria, they found more molecules associated with cellular damage from oxidative stress, cancer cell division and inflammation than mice in the control and clade 1 bacteria groups. “This supports the idea that clade 2 bacteria are contributing to this proinflammatory, pro-oncogenic environment,” Zepeda-Rivera says.

Identifying the F. nucleatum variant linked to colon cancer provides helpful insight into its role in disease development. More evidence from a larger group of people with colon cancer is needed, as well as more research to see how exactly the bacteria might contribute to inflammation and cancer progression.

Utilizing the Findings for Colon Cancer Prevention and Treatment

The study’s findings might also help in the search for a low-cost, noninvasive strategy to identify people at higher risk for colon cancer. A test could be developed to simply screen for the presence of this bacteria with a mouth swab or stool sample; clade 2 bacteria were found to be more prevalent in fecal samples from those with colon cancer, too.

In addition to diagnostic tools to predict cancer progression, the researchers also envision developing a vaccine against the F. nucleatum animalis in clade 2. This approach would be similar to that used with the human papillomavirus vaccine, which targets specific

SDGs, Targets, and Indicators

  1. SDG 3: Good Health and Well-being

    • Target 3.4: By 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.
    • Indicator 3.4.1: Mortality rate attributed to cardiovascular disease, cancer, diabetes, or chronic respiratory disease.
  2. SDG 6: Clean Water and Sanitation

    • Target 6.1: By 2030, achieve universal and equitable access to safe and affordable drinking water for all.
    • Indicator 6.1.1: Proportion of population using safely managed drinking water services.
  3. SDG 9: Industry, Innovation, and Infrastructure

    • Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and increasing the number of research and development workers per 1 million people and public and private research and development spending.
    • Indicator 9.5.1: Research and development expenditure as a proportion of GDP.

Analysis

The article discusses the connection between a specific subtype of Fusobacterium nucleatum bacteria and colon cancer. Based on the content of the article, the following SDGs, targets, and indicators can be identified:

1. SDG 3: Good Health and Well-being

The article addresses the issue of colon cancer, which falls under SDG 3’s focus on promoting good health and well-being.

2. Target 3.4: By 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

The article highlights the need to understand the genetic and environmental causes of colon cancer in order to develop better diagnostic methods and therapies, ultimately aiming to reduce premature mortality from this non-communicable disease.

3. Indicator 3.4.1: Mortality rate attributed to cardiovascular disease, cancer, diabetes, or chronic respiratory disease.

The article discusses the rise in colon cancer rates among younger people, indicating the need to measure and track mortality rates attributed to cancer, including colon cancer.

4. SDG 6: Clean Water and Sanitation

The article mentions Fusobacterium nucleatum being associated with dental plaque and gingivitis, highlighting the importance of oral hygiene and potentially linking it to clean water and sanitation.

5. Target 6.1: By 2030, achieve universal and equitable access to safe and affordable drinking water for all.

The article does not directly address this target, but it indirectly emphasizes the importance of maintaining oral health through access to safe and clean water.

6. Indicator 6.1.1: Proportion of population using safely managed drinking water services.

The article does not provide information relevant to this indicator.

7. SDG 9: Industry, Innovation, and Infrastructure

The article discusses the use of genomic research and sequencing techniques to study the Fusobacterium nucleatum bacteria, which aligns with SDG 9’s focus on enhancing scientific research and upgrading technological capabilities.

8. Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and increasing the number of research and development workers per 1 million people and public and private research and development spending.

The article highlights the use of advanced sequencing methods and emphasizes the importance of research and development in understanding the role of bacteria in colon cancer.

9. Indicator 9.5.1: Research and development expenditure as a proportion of GDP.

The article does not provide information relevant to this indicator.

Table: SDGs, Targets, and Indicators

SDGs Targets Indicators
SDG 3: Good Health and Well-being Target 3.4: By 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being. Indicator 3.4.1: Mortality rate attributed to cardiovascular disease, cancer, diabetes, or chronic respiratory disease.
SDG 6: Clean Water and Sanitation Target 6.1: By 2030, achieve universal and equitable access to safe and affordable drinking water for all. Indicator 6.1.1: Proportion of population using safely managed drinking water services.
SDG 9: Industry, Innovation, and Infrastructure Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and increasing the number of research and development workers per 1 million people and public and private research and development spending. Indicator 9.5.1: Research and development expenditure as a proportion of GDP.

Behold! This splendid article springs forth from the wellspring of knowledge, shaped by a wondrous proprietary AI technology that delved into a vast ocean of data, illuminating the path towards the Sustainable Development Goals. Remember that all rights are reserved by SDG Investors LLC, empowering us to champion progress together.

Source: scientificamerican.com

 

Join us, as fellow seekers of change, on a transformative journey at https://sdgtalks.ai/welcome, where you can become a member and actively contribute to shaping a brighter future.